Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry.

R J Fredericksen, R Baker, A Sibley, A T Estadt, D Colston, L S Mixson, S Walters, J Bresett, X A Levander, G Leichtling, T Davy-Mendez, M Powell, T J Stopka, M Pho, J Feinberg, J Ezell, W Zule, D Seal, H L F Cooper, B M Whitney, J A C Delaney, H M Crane, J I Tsui
Author Information
  1. R J Fredericksen: University of Washington, Seattle, USA. rfrederi@uw.edu.
  2. R Baker: Oregon Health & Science University, Portland, USA.
  3. A Sibley: University of North Carolina at Chapel Hill, Chapel Hill, USA.
  4. A T Estadt: The Ohio State University, Colombus, USA.
  5. D Colston: University of North Carolina at Chapel Hill, Chapel Hill, USA.
  6. L S Mixson: University of Washington, Seattle, USA.
  7. S Walters: New York University, New York, USA.
  8. J Bresett: Southern Illinois University School of Medicine, Springfield, USA.
  9. X A Levander: Oregon Health & Science University, Portland, USA.
  10. G Leichtling: Comagine Health, Portland, OR, USA.
  11. T Davy-Mendez: University of North Carolina at Chapel Hill, Chapel Hill, USA.
  12. M Powell: University of Washington, Seattle, USA.
  13. T J Stopka: Tufts University School of Medicine, Department of Public Health and Community Medicine, Medford, USA.
  14. M Pho: University of Chicago, Chicago, USA.
  15. J Feinberg: West Virginia University, Morgantown, USA.
  16. J Ezell: Cornell University, Ithaca, USA.
  17. W Zule: University of North Carolina at Chapel Hill, Chapel Hill, USA.
  18. D Seal: Tulane University, New Orleans, USA.
  19. H L F Cooper: Emory University, Atlanta, USA.
  20. B M Whitney: University of Washington, Seattle, USA.
  21. J A C Delaney: University of Washington, Seattle, USA.
  22. H M Crane: University of Washington, Seattle, USA.
  23. J I Tsui: University of Washington, Seattle, USA.

Abstract

BACKGROUND: In recent years, stimulant use has increased among persons who use opioids in the rural U.S., leading to high rates of overdose and death. We sought to understand motivations and contexts for stimulant use among persons who use opioids in a large, geographically diverse sample of persons who use drugs (PWUD) in the rural settings.
METHODS: We conducted semi-structured individual interviews with PWUD at 8 U.S. sites spanning 10 states and 65 counties. Content areas included general substance use, injection drug use, changes in drug use, and harm reduction practices. We used an iterative open-coding process to comprehensively itemize and categorize content shared by participants related to concurrent use.
RESULTS: We interviewed 349 PWUD (64% male, mean age 36). Of those discussing current use of stimulants in the context of opioid use (n = 137, 39%), the stimulant most used was methamphetamine (78%) followed by cocaine/crack (26%). Motivations for co-use included: 1) change in drug markets and cost considerations; 2) recreational goals, e.g., seeking stronger effects after heightened opioid tolerance; 3) practical goals, such as a desire to balance or alleviate the effects of the other drug, including the use of stimulants to avoid/reverse opioid overdose, and/or control symptoms of opioid withdrawal; and 4) functional goals, such as being simultaneously energized and pain-free in order to remain productive for employment.
CONCLUSION: In a rural U.S. cohort of PWUD, use of both stimulants and opioids was highly prevalent. Reasons for dual use found in the rural context compared to urban studies included changes in drug availability, functional/productivity goals, and the use of methamphetamine to offset opioid overdose. Education efforts and harm reduction services and treatment, such as access to naloxone, fentanyl test strips, and accessible drug treatment for combined opioid and stimulant use, are urgently needed in the rural U.S. to reduce overdose and other adverse outcomes.

Keywords

References

  1. PLoS One. 2020 Jun 18;15(6):e0234809 [PMID: 32555667]
  2. Int J Drug Policy. 2022 Jan;99:103467 [PMID: 34662847]
  3. Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109145 [PMID: 34763138]
  4. Drug Alcohol Depend. 2020 Jul 1;212:108060 [PMID: 32445927]
  5. Prev Med. 2021 Nov;152(Pt 2):106541 [PMID: 34482994]
  6. Subst Use Misuse. 2020;55(11):1774-1780 [PMID: 32441202]
  7. PLoS Med. 2018 Dec 26;15(12):e1002715 [PMID: 30586362]
  8. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):317-323 [PMID: 32214077]
  9. Addict Sci Clin Pract. 2022 Jul 26;17(1):38 [PMID: 35883197]
  10. Am J Public Health. 2023 Jan;113(S1):S43-S48 [PMID: 36696623]
  11. Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350 [PMID: 33965972]
  12. Drug Alcohol Depend. 2018 Dec 1;193:14-20 [PMID: 30326396]
  13. Int J Drug Policy. 2021 May;91:103098 [PMID: 33476863]
  14. Addict Sci Clin Pract. 2021 Oct 11;16(1):62 [PMID: 34635170]
  15. Int J Drug Policy. 2022 Dec;110:103896 [PMID: 36343430]
  16. Public Health Rep. 2020 May/Jun;135(3):393-400 [PMID: 32264789]
  17. Am J Addict. 2021 Mar;30(2):183-191 [PMID: 33301230]
  18. Health Promot Chronic Dis Prev Can. 2022 Feb;42(2):47-59 [PMID: 35170930]
  19. Drug Alcohol Depend. 2020 Sep 1;214:108148 [PMID: 32702620]
  20. J Subst Abuse Treat. 2021 Jul;126:108329 [PMID: 34116820]
  21. Harm Reduct J. 2020 Feb 27;17(1):14 [PMID: 32106854]
  22. Drug Alcohol Depend. 2021 Aug 1;225:108750 [PMID: 34052690]
  23. Int J Drug Policy. 2017 Oct;48:115-124 [PMID: 28734745]
  24. BMJ Open. 2022 May 2;12(5):e060447 [PMID: 35501101]
  25. JAMA Netw Open. 2022 Aug 1;5(8):e2226544 [PMID: 35969400]
  26. Drug Alcohol Depend. 2022 May 1;234:109425 [PMID: 35344879]
  27. Drug Alcohol Depend. 2019 Nov 1;204:107547 [PMID: 31536877]
  28. Subst Use Misuse. 2021;56(11):1687-1696 [PMID: 34279180]
  29. Front Psychiatry. 2022 Mar 28;13:824940 [PMID: 35418887]
  30. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):366-373 [PMID: 36207271]
  31. JAMA. 2019 Oct 1;322(13):1310-1312 [PMID: 31573628]
  32. Drug Alcohol Depend. 2020 Sep 1;214:108162 [PMID: 32652380]
  33. J Addict Med. 2023 Sep-Oct 01;17(5):615-617 [PMID: 37788621]
  34. Ann N Y Acad Sci. 2022 Feb;1508(1):3-22 [PMID: 34561865]
  35. Int J Drug Policy. 2022 Jan;99:103463 [PMID: 34619443]
  36. SAGE Open Med. 2019 Jan 02;7:2050312118822927 [PMID: 30637106]
  37. Am J Drug Alcohol Abuse. 2020 May 3;46(3):273-288 [PMID: 31809217]
  38. Drug Alcohol Depend. 2020 Nov 1;216:108307 [PMID: 33007699]
  39. J Addict Med. 2021 Jan-Feb 01;15(1):34-39 [PMID: 32530888]
  40. Drug Alcohol Depend. 2020 Aug 1;213:108131 [PMID: 32599495]
  41. J Rural Health. 2022 Jan;38(1):87-92 [PMID: 33733547]
  42. JAMA Psychiatry. 2021 Oct 1;78(10):1092-1102 [PMID: 34347030]

Grants

  1. UG3DA044829/NIDA NIH HHS
  2. UG3 DA044831/NIDA NIH HHS
  3. UH3DA044822/NIDA NIH HHS
  4. UG3DA044798/NIDA NIH HHS
  5. U24DA048538/NIDA NIH HHS
  6. K12 HS026370/AHRQ HHS
  7. UG3DA044830/NIDA NIH HHS
  8. UG3DA044831/NIDA NIH HHS
  9. U24 DA048538/NIDA NIH HHS
  10. UH3 DA044831/NIDA NIH HHS
  11. UG3DA044825/NIDA NIH HHS
  12. K01 HL169020/NHLBI NIH HHS
  13. UG3DA044826/NIDA NIH HHS
  14. UG3DA044823/NIDA NIH HHS
  15. UH3 DA044823/NIDA NIH HHS
  16. UG3 DA044798/NIDA NIH HHS
  17. UH3 DA044798/NIDA NIH HHS
  18. UG3 DA044830/NIDA NIH HHS
  19. UH3 DA044830/NIDA NIH HHS
  20. UG3 DA044823/NIDA NIH HHS
  21. UH3 DA044822/NIDA NIH HHS
  22. UG3 DA044826/NIDA NIH HHS
  23. UH3 DA044826/NIDA NIH HHS
  24. U24 DA044801/NIDA NIH HHS

MeSH Term

Humans
Male
United States
Adult
Female
Analgesics, Opioid
Opiate Overdose
Motivation
Drug Tolerance
Opioid-Related Disorders
Central Nervous System Stimulants
Methamphetamine
Drug Overdose

Chemicals

Analgesics, Opioid
Central Nervous System Stimulants
Methamphetamine

Word Cloud

Created with Highcharts 10.0.0useopioidstimulantruraldrugpersonsUSoverdosePWUDgoalsamongopioidsstimulantscontextdrugsincludedchangesharmreductionusedconcurrentmethamphetamineeffectstreatmentBACKGROUND:recentyearsincreasedleadinghighratesdeathsoughtunderstandmotivationscontextslargegeographicallydiversesamplesettingsMETHODS:conductedsemi-structuredindividualinterviews8sitesspanning10states65countiesContentareasgeneralsubstanceinjectionpracticesiterativeopen-codingprocesscomprehensivelyitemizecategorizecontentsharedparticipantsrelatedRESULTS:interviewed34964%malemeanage36discussingcurrentn = 13739%78%followedcocaine/crack26%Motivationsco-useincluded:1changemarketscostconsiderations2recreationalegseekingstrongerheightenedtolerance3practicaldesirebalancealleviateincludingavoid/reverseand/orcontrolsymptomswithdrawal4functionalsimultaneouslyenergizedpain-freeorderremainproductiveemploymentCONCLUSION:cohorthighlyprevalentReasonsdualfoundcomparedurbanstudiesavailabilityfunctional/productivityoffsetEducationeffortsservicesaccessnaloxonefentanylteststripsaccessiblecombinedurgentlyneededreduceadverseoutcomesMotivationUnitedStates:multi-sitequalitativeinquiryConcurrentMethamphetaminePolydrugRural

Similar Articles

Cited By (3)